153 related articles for article (PubMed ID: 16357512)
1. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Dahut WL; Lakhani NJ; Gulley JL; Arlen PM; Kohn EC; Kotz H; McNally D; Parr A; Nguyen D; Yang SX; Steinberg SM; Venitz J; Sparreboom A; Figg WD
Cancer Biol Ther; 2006 Jan; 5(1):22-7. PubMed ID: 16357512
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies.
Tevaarwerk AJ; Holen KD; Alberti DB; Sidor C; Arnott J; Quon C; Wilding G; Liu G
Clin Cancer Res; 2009 Feb; 15(4):1460-5. PubMed ID: 19228747
[TBL] [Abstract][Full Text] [Related]
3. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
Zhou Q; Gustafson D; Nallapareddy S; Diab S; Leong S; Lewis K; Gore L; Messersmith WA; Treston AM; Eckhardt SG; Sidor C; Camidge DR
Invest New Drugs; 2011 Apr; 29(2):340-6. PubMed ID: 20084425
[TBL] [Abstract][Full Text] [Related]
4. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
James J; Murry DJ; Treston AM; Storniolo AM; Sledge GW; Sidor C; Miller KD
Invest New Drugs; 2007 Feb; 25(1):41-8. PubMed ID: 16969706
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).
Harrison MR; Hahn NM; Pili R; Oh WK; Hammers H; Sweeney C; Kim K; Perlman S; Arnott J; Sidor C; Wilding G; Liu G
Invest New Drugs; 2011 Dec; 29(6):1465-74. PubMed ID: 20499131
[TBL] [Abstract][Full Text] [Related]
6. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
Kulke MH; Chan JA; Meyerhardt JA; Zhu AX; Abrams TA; Blaszkowsky LS; Regan E; Sidor C; Fuchs CS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):293-300. PubMed ID: 20960192
[TBL] [Abstract][Full Text] [Related]
7. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent.
Mooberry SL
Curr Opin Oncol; 2003 Nov; 15(6):425-30. PubMed ID: 14624224
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of 2-methoxyestradiol: new developments.
Mooberry SL
Drug Resist Updat; 2003 Dec; 6(6):355-61. PubMed ID: 14744499
[TBL] [Abstract][Full Text] [Related]
9. Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis.
Plum SM; Park EJ; Strawn SJ; Moore EG; Sidor CF; Fogler WE
BMC Musculoskelet Disord; 2009 May; 10():46. PubMed ID: 19409094
[TBL] [Abstract][Full Text] [Related]
10. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
Ricker JL; Chen Z; Yang XP; Pribluda VS; Swartz GM; Van Waes C
Clin Cancer Res; 2004 Dec; 10(24):8665-73. PubMed ID: 15623651
[TBL] [Abstract][Full Text] [Related]
11. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.
Matei D; Schilder J; Sutton G; Perkins S; Breen T; Quon C; Sidor C
Gynecol Oncol; 2009 Oct; 115(1):90-96. PubMed ID: 19577796
[TBL] [Abstract][Full Text] [Related]
12. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
Milojkovic Kerklaan B; Slater S; Flynn M; Greystoke A; Witteveen PO; Megui-Roelvink M; de Vos F; Dean E; Reyderman L; Ottesen L; Ranson M; Lolkema MP; Plummer R; Kristeleit R; Evans TR; Schellens JH
Invest New Drugs; 2016 Jun; 34(3):329-37. PubMed ID: 27039386
[TBL] [Abstract][Full Text] [Related]
13. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
Rajkumar SV; Richardson PG; Lacy MQ; Dispenzieri A; Greipp PR; Witzig TE; Schlossman R; Sidor CF; Anderson KC; Gertz MA
Clin Cancer Res; 2007 Oct; 13(20):6162-7. PubMed ID: 17947482
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.
Marshall JL; Kindler H; Deeken J; Bhargava P; Vogelzang NJ; Rizvi N; Luhtala T; Boylan S; Dordal M; Robertson P; Hawkins MJ; Ratain MJ
Invest New Drugs; 2005 Jan; 23(1):31-7. PubMed ID: 15528978
[TBL] [Abstract][Full Text] [Related]
15. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor.
Brahn E; Banquerigo ML; Lee JK; Park EJ; Fogler WE; Plum SM
J Rheumatol; 2008 Nov; 35(11):2119-28. PubMed ID: 18792999
[TBL] [Abstract][Full Text] [Related]
16. Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol.
Lakhani N; Sparreboom A; Venitz J; Dahut WL; Figg WD
Anticancer Drugs; 2006 Sep; 17(8):977-83. PubMed ID: 16940808
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
Clark JW; Eder JP; Ryan D; Lathia C; Lenz HJ
Clin Cancer Res; 2005 Aug; 11(15):5472-80. PubMed ID: 16061863
[TBL] [Abstract][Full Text] [Related]
18. Effective transscleral delivery of two retinal anti-angiogenic molecules: carboxyamido-triazole (CAI) and 2-methoxyestradiol (2ME2).
Cruysberg LP; Franklin AJ; Sanders J; Self C; Yuan P; Csaky KG; Robinson MR; Kohn EC; Edelhauser HF
Retina; 2005 Dec; 25(8):1022-31. PubMed ID: 16340533
[TBL] [Abstract][Full Text] [Related]
19. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.
LaVallee TM; Burke PA; Swartz GM; Hamel E; Agoston GE; Shah J; Suwandi L; Hanson AD; Fogler WE; Sidor CF; Treston AM
Mol Cancer Ther; 2008 Jun; 7(6):1472-82. PubMed ID: 18566218
[TBL] [Abstract][Full Text] [Related]
20. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
